Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Grogan

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
Human Pathology|May 23, 2000
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survivalT M Grogan, C Fenoglio-Prieser, R Zeheb, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1995
Generation of cytotoxic effector cells against human melanomaS P Leong, Y M Zhou, M E Granberry, et al.
Diagnostic Immunology|January 1, 1985
Immunotopography of splenic lymphoma of small cleaved B-cell typeT M Grogan, C S Rangel, D P Wirt, et al.
Blood|April 1, 1988
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67T M Grogan, S M Lippman, C M Spier, et al.
American Journal of Clinical Pathology|March 1, 1985
Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypesT M Grogan, K Fielder, C Rangel, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|January 1, 1988
A comprehensive immunotopographic map of human thymusD P Wirt, T M Grogan, R B Nagle, et al.
Blood|February 15, 1989
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulationW S Dalton, T M Grogan, J A Rybski, et al.
The New England Journal of Medicine|July 2, 1998
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphomaT P Miller, S Dahlberg, J R Cassady, et al.
The New England Journal of Medicine|April 8, 1993
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomaR I Fisher, E R Gaynor, S Dahlberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma StudyR I Fisher, E R Gaynor, S Dahlberg, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
Human Pathology|May 23, 2000
Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survivalT M Grogan, C Fenoglio-Prieser, R Zeheb, et al.
Cancer Immunology, Immunotherapy : CII|June 1, 1995
Generation of cytotoxic effector cells against human melanomaS P Leong, Y M Zhou, M E Granberry, et al.
Diagnostic Immunology|January 1, 1985
Immunotopography of splenic lymphoma of small cleaved B-cell typeT M Grogan, C S Rangel, D P Wirt, et al.
Blood|April 1, 1988
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67T M Grogan, S M Lippman, C M Spier, et al.
American Journal of Clinical Pathology|March 1, 1985
Peripheral T-cell lymphoma: aggressive disease with heterogeneous immunotypesT M Grogan, K Fielder, C Rangel, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|January 1, 1988
A comprehensive immunotopographic map of human thymusD P Wirt, T M Grogan, R B Nagle, et al.
Blood|February 15, 1989
Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulationW S Dalton, T M Grogan, J A Rybski, et al.
The New England Journal of Medicine|July 2, 1998
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphomaT P Miller, S Dahlberg, J R Cassady, et al.
The New England Journal of Medicine|April 8, 1993
Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphomaR I Fisher, E R Gaynor, S Dahlberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma StudyR I Fisher, E R Gaynor, S Dahlberg, et al.
Pageof 15